Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,308 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
Interventions: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Diclofenac, Celecoxib, Matching placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 71
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Conditions: Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome, Postmenopausal Symptoms, Menopause
Interventions: Prasterone, Placebo; Drug
Lead sponsor: Olivia Cardenas-Trowers, M.D.; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Prevention of Pregnancy
Interventions: Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 938 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more

Conditions: Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions: Cabiralizumab, Nivolumab; Biological
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 39
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 56
States / cities: Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more

Conditions: Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions: Intensity-Modulated Radiation Therapy; Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Bakersfield, California • Greenbrae, California • Los Angeles, California + 97 more

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enclitide Chloride, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 20
States / cities: Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more

Conditions: Pterygium
Interventions: CBT-001, Vehicle; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 60
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 38 more

Conditions: Dry Eye Disease
Interventions: OK-101, Placebo; Drug
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 99 Years
Enrollment: 12,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 140
States / cities: Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more

Conditions: Unresectable Melanoma, Metastatic Melanoma
Interventions: OOS AMTAGVI; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 48
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 36 more

Conditions: Herpes Simplex
Interventions: Valaciclovir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Dermatitis, Atopic
Interventions: LY3454738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Anniston, Alabama • North Little Rock, Arkansas • Rogers, Arkansas + 16 more

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, mRNA-1283, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Conditions: Acne Vulgaris
Interventions: Zileuton; Drug
Lead sponsor: Critical Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 12
States / cities: San Diego, California • Newnan, Georgia • Louisville, Kentucky + 9 more

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more

Conditions: Ovarian Cancer
Interventions: Olaparib, Ceralasertib, Placebo to match olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more

Conditions: Endometrial Carcinoma
Interventions: GDC-0980; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Newport Beach, California • Orange, California + 23 more

Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Interventions: Total Knee Arthroplasty; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 16
States / cities: Parker, Colorado • Tampa, Florida • Atlanta, Georgia + 13 more

Conditions: Recent Onset type1 Diabetes
Interventions: Ladarixin, Placebo; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 14 Years to 45 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more

Search by objective public record fields.

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

Study of Safety and Efficacy of an Oral Contraceptive

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function